Literature DB >> 9311822

A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity.

S Nekhai1, R R Shukla, A Kumar.   

Abstract

Tat protein mediates transactivation of human immunodeficiency virus type 1 (HIV-1), which results in more-efficient transcript elongation. Since phosphorylation of C-terminal domain (CTD) of RNA polymerase II correlates with its enhanced processivity, we studied the properties of a Tat-associated CTD kinase derived from mitogenically stimulated human primary T lymphocytes (TTK). TTK binds to full-length Tat and specifically phosphorylates CTD and CDK2. This dual kinase activity is characteristic of CDK-activating kinase (CAK). The CTD kinase activity is induced upon mitogenic stimulation of primary T lymphocytes. Fractionation of T-cell lysate demonstrates that Tat-associated CTD kinase activity elutes in two peaks. About 60% of Tat-associated CTD kinase copurifies with CDK2 kinase activity and contains the CAK components CDK7 and cyclin H. The rest of Tat-associated kinase is free of CDK2 kinase activity and the CAK components and thus may represent a novel CTD kinase. The kinase activities of TTK are blocked by the adenosine analog 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole (DRB) as well as by the kinase inhibitor H8 at concentrations known to block transcript elongation. Importantly, the Tat-associated kinase markedly induced CAK. We suggest that the mechanism of Tat-mediated processive transcription of the HIV-1 promoter includes a Tat-associated CAK activator.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311822      PMCID: PMC192089          DOI: 10.1128/JVI.71.10.7436-7441.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain.

Authors:  C A Parada; R G Roeder
Journal:  Nature       Date:  1996-11-28       Impact factor: 49.962

Review 2.  Common themes in assembly and function of eukaryotic transcription complexes.

Authors:  L Zawel; D Reinberg
Journal:  Annu Rev Biochem       Date:  1995       Impact factor: 23.643

3.  Specific binding of RNA polymerase II to the human immunodeficiency virus trans-activating region RNA is regulated by cellular cofactors and Tat.

Authors:  F Wu-Baer; D Sigman; R B Gaynor
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

4.  Viral transactivators specifically target distinct cellular protein kinases that phosphorylate the RNA polymerase II C-terminal domain.

Authors:  C H Herrmann; M O Gold; A P Rice
Journal:  Nucleic Acids Res       Date:  1996-02-01       Impact factor: 16.971

5.  Transcription revisited: a commentary on the 1995 Cold Spring Harbor Laboratory meeting, "Mechanisms of Eukaryotic Transcription".

Authors:  S L McKnight
Journal:  Genes Dev       Date:  1996-02-15       Impact factor: 11.361

6.  Interaction of human immunodeficiency virus type 1 Tat with a unique site of TFIID inhibits negative cofactor Dr1 and stabilizes the TFIID-TFIIA complex.

Authors:  F Kashanchi; S N Khleif; J F Duvall; M R Sadaie; M F Radonovich; M Cho; M A Martin; S Y Chen; R Weinmann; J N Brady
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 and 2 Tat proteins specifically interact with RNA polymerase II.

Authors:  G Mavankal; S H Ignatius Ou; H Oliver; D Sigman; R B Gaynor
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

8.  Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat.

Authors:  Q Zhou; P A Sharp
Journal:  Science       Date:  1996-10-25       Impact factor: 47.728

9.  Human immunodeficiency virus type-1 Tat is an integral component of the activated transcription-elongation complex.

Authors:  N J Keen; M J Gait; J Karn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

10.  In vitro assembly of a functional human CDK7-cyclin H complex requires MAT1, a novel 36 kDa RING finger protein.

Authors:  J P Tassan; M Jaquenoud; A M Fry; S Frutiger; G J Hughes; E A Nigg
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

View more
  13 in total

1.  Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator.

Authors:  F Kashanchi; E T Agbottah; C A Pise-Masison; R Mahieux; J Duvall; A Kumar; J N Brady
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.

Authors:  D Wang; C de la Fuente; L Deng; L Wang; I Zilberman; C Eadie; M Healey; D Stein; T Denny; L E Harrison; L Meijer; F Kashanchi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Functional interactions between herpesvirus oncoprotein MEQ and cell cycle regulator CDK2.

Authors:  J L Liu; Y Ye; Z Qian; Y Qian; D J Templeton; L F Lee; H J Kung
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription.

Authors:  Sergei Nekhai; Meisheng Zhou; Anne Fernandez; William S Lane; Ned J C Lamb; John Brady; Ajit Kumar
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

5.  9-Aminoacridine inhibition of HIV-1 Tat dependent transcription.

Authors:  Irene Guendel; Lawrence Carpio; Rebecca Easley; Rachel Van Duyne; William Coley; Emmanuel Agbottah; Cynthia Dowd; Fatah Kashanchi; Kylene Kehn-Hall
Journal:  Virol J       Date:  2009-07-24       Impact factor: 4.099

6.  Human GLI-2 is a tat activation response element-independent Tat cofactor.

Authors:  C M Browning; M J Smith; N M Clark; B R Lane; C Parada; M Montano; V N KewalRamani; D R Littman; M Essex; R G Roeder; D M Markovitz
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  CDK13, a new potential human immunodeficiency virus type 1 inhibitory factor regulating viral mRNA splicing.

Authors:  Reem Berro; Caitlin Pedati; Kylene Kehn-Hall; Weilin Wu; Zachary Klase; Yasmine Even; Anne-Marie Genevière; Tatiana Ammosova; Sergei Nekhai; Fatah Kashanchi
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

Review 8.  Replication of human immunodeficiency virus type 1 from entry to exit.

Authors:  Andrew M L Lever; Kuan-Teh Jeang
Journal:  Int J Hematol       Date:  2006-07       Impact factor: 2.490

Review 9.  Marek's disease herpesvirus transforming protein MEQ: a c-Jun analogue with an alternative life style.

Authors:  J L Liu; H J Kung
Journal:  Virus Genes       Date:  2000       Impact factor: 2.198

Review 10.  Tat gets the "green" light on transcription initiation.

Authors:  John Brady; Fatah Kashanchi
Journal:  Retrovirology       Date:  2005-11-09       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.